Literature DB >> 29845894

Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.

Suyeon Park1,2, Min Ji Jeon1, Hye-Seon Oh1, Yu-Mi Lee3, Tae-Yon Sung3, Minkyu Han4, Ji Min Han5, Tae Yong Kim1, Ki-Wook Chung3, Won Bae Kim1, Young Kee Shong1, Won Gu Kim1.   

Abstract

BACKGROUND: Low-risk patients with differentiated thyroid cancer can be treated with thyroid lobectomy. Serial measurements of serum thyroglobulin (Tg) are recommended for surveillance, but the cutoff values indicating recurrence are not known. This study documented the natural course of serum Tg levels during follow-up after lobectomy for low-risk papillary thyroid carcinoma (PTC) and evaluated whether changes in serum Tg levels predict disease recurrence.
METHODS: This historical cohort study included 208 patients with low-risk PTC who underwent lobectomy but did not require hormone replacement. Postoperative serum Tg levels and Tg/thyrotropin (TSH) ratios and neck ultrasound were evaluated during a follow-up period with a median of 6.9 years.
RESULTS: The serum Tg levels increased gradually, and the proportion of patients with levels >10 ng/dL increased annually by 13.9%, 18.8%, 22.1%, 21.9%, 28.4%, and 28.9% during the six-year follow-up period (β = 0.574, p = 0.027). The relative serum Tg levels increased by 10% annually (β = 0.105, p < 0.001), and the levels of Tg and Tg/TSH ratios in 19 patients with recurrent disease did not differ significantly (β = 0.150, p = 0.090). Patients without recurrent disease were more likely to have serum Tg levels increased by >20% (p = 0.022). There were no significant differences in the proportions of patients with serum Tg levels increased by ≥50% or ≥100% in terms of the disease recurrence.
CONCLUSIONS: Serum Tg levels and the Tg/TSH ratio increased gradually after lobectomy in patients with and without recurrences, without any significant differences. Periodic measurements of serum Tg levels seem to have limited value in predicting recurrent PTCs after lobectomy.

Entities:  

Keywords:  lobectomy; low risk; recurrence; thyroglobulin; thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 29845894     DOI: 10.1089/thy.2018.0046

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  11 in total

1.  Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents.

Authors:  Dongmei Huang; Jingtai Zhi; Jinming Zhang; Xuan Qin; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 2.  The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.

Authors:  Pavel V Belousov
Journal:  Biomedicines       Date:  2022-02-17

3.  Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review.

Authors:  Carla Colombo; Simone De Leo; Marta Di Stefano; Matteo Trevisan; Claudia Moneta; Leonardo Vicentini; Laura Fugazzola
Journal:  Ann Surg Oncol       Date:  2021-02-10       Impact factor: 5.344

4.  A Novel Role of Galectin-3 and Thyroglobulin in Prognosis and Differentiation of Different Stages of Thyroid Cancer and Elucidation of the Potential Contribution of Bcl-2, IL-8 and TNF-α.

Authors:  Tarek M Okda; Gamal M K Atwa; Ahmed Fathy Eldehn; Naief Dahran; Khalaf F Alsharif; Ehab Kotb Elmahallawy
Journal:  Biomedicines       Date:  2022-02-01

5.  Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives.

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Eur Thyroid J       Date:  2018-11-16

6.  Natural Course of the American Thyroid Association Response to Therapy Statuses (Dynamic Risk Stratification) in Differentiated Thyroid Cancer.

Authors:  Noha Mukhtar; Hadeel Aljamei; Abeer Aljomaiah; Yosra Moria; Ali S Alzahrani
Journal:  Eur Thyroid J       Date:  2020-12-01

7.  Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma.

Authors:  Bo Young Kim; Nayeon Choi; Sun Wook Kim; Han-Sin Jeong; Man Ki Chung; Young- Ik Son
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-29       Impact factor: 3.236

Review 8.  Hemithyroidectomy for Thyroid Cancer: A Review.

Authors:  Noor Addasi; Abbey Fingeret; Whitney Goldner
Journal:  Medicina (Kaunas)       Date:  2020-11-03       Impact factor: 2.430

9.  Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma.

Authors:  Fuxin Li; Wei Li; Katherine D Gray; Rasa Zarnegar; Dan Wang; Thomas J Fahey
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

Review 10.  Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.

Authors:  Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.